What is Infinity Pharmaceuticals, Inc. (INFIQ)?

Infinity Pharmaceuticals, Inc. (INFIQ) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of INFIQ?

The current price of INFIQ is $0.00. Prices are updated in real time on Stocks360.

What is INFIQ's price-to-earnings (PE) ratio?

INFIQ's trailing twelve-month PE ratio is -0.00, based on current price and earnings per share data available on Stocks360.

What is INFIQ's market capitalization?

INFIQ's market capitalization is $9,076.00, placing it in the small-cap tier.

Infinity Pharmaceuticals, Inc. (INFIQ)

Stock analysis · OTC · Healthcare · Biotechnology

$0.00

Market Cap

$9.08K

PE (TTM)

-0.00

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

8.97

Day Range

$0.00 – $0.00

52-wk Range

$0.00 – $0.00

Avg Volume

N/A

Volume

109.40K

Infinity Pharmaceuticals, Inc. (INFIQ) is a publicly traded company in the Healthcare sector. Latest price: $0.00. Market cap $9.08K. Trailing PE -0.00. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-29 · $0.00 2026-10-27 · $0.00 (+9900.00%)

Earnings

Most Recent

Aug 10, 2023

EPS $-0.11 vs est. $-0.12

Beat by $0.01

Next Earnings

Nov 16, 2026

EPS estimate $-0.13

Proprietary Signals

Signal snapshot temporarily unavailable.

About Infinity Pharmaceuticals, Inc.

Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. The company's product candidate, including eganelisib (IPI-549), an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. Infinity Pharmaceuticals, Inc. has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Cambridge, Massachusetts. On September 29, 2023, Infinity P…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.00×
P/S (TTM)	0.00×
P/B	-0.00×
PEG	0.00×
P/FCF (TTM)	-0.00×
EV / EBITDA	-0.22×
EV / Sales	3.79×
Earnings Yield	-497143.99%
Free Cash Flow Yield	-467695.02%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$9.83M
Revenue (TTM)	$2.59M
Net Income (TTM)	-$45.12M
Free Cash Flow (TTM)	-$42.27M
Net Debt	$9.82M
Working Capital	$26.67M
Gross Margin	39.72%
Operating Margin	-1729.43%
Net Margin	-1711.11%
Return on Equity	-3521.35%
Return on Invested Capital	-154.02%